Browse the evidence

Gastrointestinal adverse events, including nausea, vomiting, diarrhea, and constipation, are frequent side effects of tirzepatide, particularly during initiation and titration phases.

GI side effects like nausea and diarrhea are common with tirzepatide, especially when starting or increasing the dose. Talk to your doctor about managing these symptoms with diet changes or medication to help you stay on treatment.

Other protein supplements (soy, casein, pea, rice, etc.) do not show statistically significant differences in muscle strength or fat-free mass gains compared to placebo in healthy adults undergoing resistance training.

If you are using other protein supplements like soy, casein, or pea protein, they may not provide significant additional benefits for muscle strength or mass gains compared to a placebo. Focus on collagen or whey if you want to maximize your results.

Targeting endogenous enteroendocrine cell (EEC) secretion to mimic postprandial hypersecretion of GLP-1 and other GI hormones offers a potential treatment for obesity and type 2 diabetes that avoids the side effects of exogenous GLP-1-based drugs.

Current research suggests that stimulating your gut to release its own GLP-1 (perhaps through specific nutrients or future drugs) might help with weight loss and blood sugar control without the nausea or nutrient malabsorption seen with current GLP-1 injections. This is still experimental.

GLP-1 receptor agonist pharmacotherapy in older adults causes significant loss of lean skeletal muscle mass (approx. 26-40% of total weight lost), which independently predicts adverse outcomes including mortality, functional decline, and frailty.

If you are an older adult using GLP-1 medications, do not focus solely on the number on the scale. The medication causes you to lose muscle along with fat, which can lead to frailty and higher mortality. You must actively counteract this by combining your medication with resistance exercise and adequate protein intake to preserve your muscle mass.

Semaglutide induces adipose tissue remodeling in Type 2 Diabetes by promoting mitochondrial biogenesis, inducing beige adipocyte programming, and reducing visceral adiposity, leading to improved systemic insulin sensitivity and reduced ectopic fat deposition.

For individuals with T2DM or obesity, semaglutide offers benefits that go beyond simple weight loss. It actively remodels fat tissue, particularly visceral fat, making it more metabolically active and less inflammatory. This leads to improved insulin sensitivity and reduced liver fat, which are critical for long-term metabolic health. The medication is taken once weekly, with doses tailored to whether the goal is managing diabetes (up to 1.0 mg) or weight loss (up to 2.4 mg).

Tirzepatide promotes sustained improvements in skeletal muscle mitochondrial respiration and ATP production under lipotoxic conditions, whereas semaglutide and cagrilintide cause transient suppression that resolves over time.

If you are using incretin-based therapies like tirzepatide, this in vitro evidence suggests your muscle cells may become more efficient at producing energy over time, even under metabolic stress. While other drugs in this class (semaglutide, cagrilintide) show temporary dips in mitochondrial function, tirzepatide appears to enhance it. This supports the importance of resistance training to leverage these cellular adaptations for maintaining muscle quality.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with a signal for tumorigenesis, specifically thyroid and pancreatic cancers, with risk profiles varying significantly by patient age, sex, and body weight.

If you are considering or using a GLP-1 medication (like Ozempic or Wegovy), be aware that there is a detected signal for thyroid and pancreatic tumors in large-scale reporting databases. This risk is not uniform: it appears more frequently in women (thyroid) and older men (pancreas). You should discuss your specific age, sex, and family history with your doctor to weigh these potential risks against the significant benefits of blood sugar and weight management.

Postmarketing reports of neoplasms are higher for GLP-1 RAs compared to non-GLP-1 agents, but remain rare relative to overall exposure.

While postmarketing reports of neoplasms are higher for GLP-1 RAs, they are still rare. The benefits of weight loss and mortality reduction likely outweigh this small risk for most patients.

Primary care physicians' proactivity in prescribing pharmaceutical weight loss treatments is significantly correlated with their belief in the efficacy of those treatments and their specific knowledge of the agents, whereas lack of knowledge is the predominant barrier for less proactive physicians.

For primary care physicians, the key to expanding obesity treatment options is not just access to drugs, but targeted education and clear guidelines. Physicians who feel knowledgeable and confident are significantly more likely to prescribe effective pharmaceutical interventions like liraglutide. Updating guidelines and providing continuous education can directly increase proactive prescribing.

Semaglutide is associated with a higher incidence of symptomatic gastrointestinal adverse events compared to dulaglutide in the context of emergency exposures.

If you experience severe nausea or vomiting on semaglutide, talk to your doctor. They might switch you to a different GLP-1 medication, like dulaglutide, which may have fewer gastrointestinal side effects for you.

Combining calcium beta-hydroxy-beta-methylbutyrate (CaHMB) supplementation with resistance training amplifies body fat reduction compared to resistance training alone, mediated by increased FNDC-5 gene expression and irisin concentration in white adipose tissue.

If you are doing resistance training, adding CaHMB (320 mg/kg/day) may help you lose more body fat than training alone by boosting irisin levels in fat tissue. This is based on rat studies, so human dosing may vary, but the synergy between the supplement and exercise is clear.

Resistance training does not significantly alter myofibrillar or sarcoplasmic protein concentrations (densities) in either high or low anabolic responders over 12 weeks.

Don't worry about 'protein density' supplements or specific diets to change it. Muscle growth happens by adding structure, not by packing existing structure tighter. Consistent training is sufficient.

Cultural insularity, defined as the greater role of cultural identity in food choices, is positively associated with higher BMI in French populations.

If you live in a culture where food is central to identity, weight management may feel like a betrayal of your community. Recognize that 'cultural insularity'—letting cultural norms dictate food choices—is a real, measurable factor linked to higher BMI. To manage weight, focus on integrating health into your culture (e.g., modifying traditional dishes) rather than rejecting your heritage, as this reduces the psychological resistance to change.

Obesity involves molecular mechanisms, including metabolic memory and epigenetic modifications, that actively hinder weight loss and promote weight regain.

If you are struggling to lose weight despite diet and exercise, recognize that your body has biological defenses (like metabolic memory and hormonal shifts) that actively work to restore previous weight. This is not a failure of willpower but a known physiological response. Addressing these barriers may require a multidisciplinary approach, potentially including medical interventions, rather than just stricter dieting.

Epigenetic changes, such as DNA methylation and histone modifications, can persist after weight loss and contribute to weight regain.

Weight loss can trigger long-lasting epigenetic changes that make your body more prone to regaining weight. This means maintaining weight loss might require ongoing effort and potentially medical support, as your body's 'default setting' may have shifted.

Adipose tissue dysfunction, characterized by chronic low-grade inflammation and insulin resistance, creates a self-perpetuating cycle that promotes obesity.

Excess fat, especially around the abdomen, is not just inert storage but an active organ that releases inflammatory signals. These signals can cause insulin resistance and further fat storage, creating a cycle that is hard to break without addressing the underlying inflammation.

Rapid and significant weight loss induced by Tirzepatide leads to aesthetic changes, including facial volume loss ('Ozempic face'), skin laxity, and altered collagen structure, which are secondary to fat loss rather than direct drug toxicity.

Significant weight loss can cause your face to look older or saggy due to loss of facial fat. This is a side effect of the weight loss, not the drug itself. Eating enough protein and vitamins (like D and B12) during treatment may help maintain skin health.

GLP-1 receptor agonists may interact with oral systemic cancer therapies by delaying gastric emptying, potentially altering absorption kinetics (time to peak concentration) without necessarily changing total drug exposure.

If you take oral cancer pills along with GLP-1 drugs (like Ozempic), tell your doctor. The GLP-1 drug might slow down how fast your cancer pills are absorbed. This doesn't always mean the treatment won't work, but your doctor needs to know to monitor you closely.

GLP-1 receptor agonist consumption in Brazil is driven by socioeconomic capacity and access rather than epidemiological need, as evidenced by a significant positive correlation with GDP per capita and no correlation with obesity prevalence.

In Brazil, access to GLP-1 drugs like semaglutide is currently determined by your state's economic wealth rather than your obesity rates. Public health policy has excluded these drugs from free coverage, creating a market where only those with higher income can afford them, regardless of medical need.

Semaglutide is the predominant GLP-1 RA in Brazil, driving the majority of sales growth and adverse event reports, with significant off-label use for weight loss.

Semaglutide is the most widely used GLP-1 drug in Brazil. A significant portion of its use is off-label for weight loss, which generates specific adverse event reports and requires careful monitoring.

Oriental Melon Stem Ethanol Extract (CMSE) reduces body weight and fat mass in high-fat diet-induced obese mice by increasing energy expenditure and enhancing brown adipose tissue thermogenesis, independent of calorie intake.

If you are looking for a supplement to support weight management, Oriental Melon Stem Extract (CMSE) shows promise in animal studies for boosting metabolism and burning fat without needing to eat less. The effective dose in mice translates to a high daily intake for humans (~2.3g), which falls within the range of dietary supplements. While not a magic bullet, it may support metabolic health and liver function when combined with a balanced diet.

GLP-1 receptor agonist therapy (semaglutide/tirzepatide) is increasingly driving referrals for post-weight-loss body contouring, with referral volumes growing faster than those from lifestyle modification or bariatric surgery.

If you are using GLP-1 medications like Ozempic or Mounjaro, be aware that rapid weight loss often leads to excess skin. You may need to consult a plastic surgeon for body contouring procedures. This is a common and expected outcome of significant weight loss via these medications.

In type 2 diabetes, worsening chronic glycaemic control (higher HbA1c) shifts endogenous GIP action from insulinotropic to glucagonotropic, strengthening the correlation between GIP and glucagon secretion while weakening its correlation with insulin.

For people with Type 2 Diabetes, the effectiveness of the body's natural GIP response depends heavily on how well blood sugar is controlled. If HbA1c is high, GIP may contribute to higher glucagon (raising blood sugar) rather than helping insulin. This suggests that managing baseline blood sugar is crucial for optimizing natural hormonal responses.

Expanding first-level genetic screening for obesity to include POMC and MC3R genes is necessary to maximize diagnostic yield and identify patients with intermediate susceptibility phenotypes who are missed by standard panels.

If you have obesity and standard genetic tests came back negative, ask your doctor about expanded testing for POMC and MC3R genes. This can reveal if you have a specific biological susceptibility that might affect how your body handles energy, potentially guiding more personalized treatment strategies.